These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 4015735)
1. Calcium antagonistic properties of nicardipine, a dihydropyridine derivative assessed in isolated cerebral arteries and cardiac muscle. Nakayama K; Kurihara J; Miyajima Y; Ishii K; Kato H Arzneimittelforschung; 1985; 35(4):687-93. PubMed ID: 4015735 [TBL] [Abstract][Full Text] [Related]
2. Cerebrovascular selectivity and vasospasmolytic action of the novel calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate in isolated cerebral arteries of the rabbit and dog. Minato H; Hashizume M; Masuda Y; Fujitani B; Hosoki K Arzneimittelforschung; 1997 Apr; 47(4):339-46. PubMed ID: 9150852 [TBL] [Abstract][Full Text] [Related]
3. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro. Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604 [TBL] [Abstract][Full Text] [Related]
4. Effects of nilvadipine on the cardiovascular system in experimental animals. Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444 [TBL] [Abstract][Full Text] [Related]
5. Tissue selectivity of the novel calcium antagonist sesamodil fumarate in isolated smooth muscles and cardiac muscles. Nishimura K; Miyawaki N; Yamauchi H; Iso T Arzneimittelforschung; 1990 Mar; 40(3):244-8. PubMed ID: 2112000 [TBL] [Abstract][Full Text] [Related]
6. Nicardipine actions on smooth muscle cells and neuromuscular transmission in the guinea-pig basilar artery. Fujiwara S; Kuriyama H J Pharmacol Exp Ther; 1983 May; 225(2):447-55. PubMed ID: 6302249 [TBL] [Abstract][Full Text] [Related]
7. Vascular and cardiac effects of a new dihydropyridine derivative, YC-170: a comparison with Bay K 8644. Hattori Y; Nakaya H; Tohse N; Kanno M J Pharmacol Exp Ther; 1986 Aug; 238(2):670-8. PubMed ID: 2426442 [TBL] [Abstract][Full Text] [Related]
8. Effect of ryodipine on electromechanical parameters of heart and vessels, cAMP phosphodiesterase activity and swelling-contraction cycle of mitochondria. Velena AH; Dubur GJ; Vitolina RO; Kimenis AA; Selga MJ; Zarinsh GV; Narusevicius EV; Macianskiene RA; Gendvilienè VI; Simkhovich BZ Arzneimittelforschung; 1985; 35(6):907-14. PubMed ID: 2992533 [TBL] [Abstract][Full Text] [Related]
9. Effects of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the responses of isolated canine arteries. Kanda M; Shirahase H; Kurahashi K; Wada K; Nakamura S; Matsui H; Fukata F Arzneimittelforschung; 1995 Aug; 45(8):831-5. PubMed ID: 7575741 [TBL] [Abstract][Full Text] [Related]
10. Assessment in pig coronary artery of long-lasting and potent calcium antagonistic actions of the novel dihydropyridine derivative mepirodipine hydrochloride. Nakayama K; Kashiwabara T; Yamada S; Tanaka Y Arzneimittelforschung; 1989 Jan; 39(1):50-5. PubMed ID: 2470382 [TBL] [Abstract][Full Text] [Related]
11. Effects of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the endothelium-independent and endothelium-dependent contraction in isolated canine cerebral arteries. Kanda M; Shirahase H; Wada K; Nakamura S; Matsui H; Fukata F Arzneimittelforschung; 1996 Jul; 46(7):663-6. PubMed ID: 8842332 [TBL] [Abstract][Full Text] [Related]
12. Vasodilatory properties in vascular smooth muscle of the calcium antagonist NB-818 compared to nicardipine and nimodipine. Nishikibe M; Fukuroda T; Nakajima A Arch Int Pharmacodyn Ther; 1989; 297():98-111. PubMed ID: 2730244 [TBL] [Abstract][Full Text] [Related]
13. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. Yamaura T; Kase N; Kita H; Uematsu T Arzneimittelforschung; 1986; 36(1):29-34. PubMed ID: 3754142 [TBL] [Abstract][Full Text] [Related]
14. Calcium channel modulation: ability to inhibit or promote calcium influx resides in the same dihydropyridine molecule. Thomas G; Gross R; Schramm M J Cardiovasc Pharmacol; 1984; 6(6):1170-6. PubMed ID: 6084776 [TBL] [Abstract][Full Text] [Related]
15. Effects of the new calcium antagonist 2-nitratopropyl-3-nitratopropyl-2,6-dimethyl-4-(3-nitrophe nyl)- 1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in dogs. Tsuchida K; Yamazaki R; Kaneko K; Aihara H Arzneimittelforschung; 1987 Nov; 37(11):1239-43. PubMed ID: 3481545 [TBL] [Abstract][Full Text] [Related]
16. In vitro effects of calcium antagonists PN 200-110, nifedipine, and nimodipine on human and canine cerebral arteries. Müller-Schweinitzer E; Neumann P J Cereb Blood Flow Metab; 1983 Sep; 3(3):354-61. PubMed ID: 6223932 [TBL] [Abstract][Full Text] [Related]
17. Agonist actions of Bay K 8644, a dihydropyridine derivative, on the voltage-dependent calcium influx in smooth muscle cells of the rabbit mesenteric artery. Kanmura Y; Itoh T; Kuriyama H J Pharmacol Exp Ther; 1984 Dec; 231(3):717-23. PubMed ID: 6209390 [TBL] [Abstract][Full Text] [Related]
18. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding. Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181 [TBL] [Abstract][Full Text] [Related]